Improvement of mCAR20-T cell therapy upon incorporation of NAP implies that the therapy could be evaluated for patients with CD20-positive refractory or relapsed (r/r) B cell lymphomas, possibly also after relapse from CD19 CAR-T cell treatment. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.